Evidence map›Paper›PMID 33188364›Full record

ReviewNature reviews. Endocrinology2021

COVID-19 and diabetes mellitus: from pathophysiology to clinical management.

Soo Lim, Jae Hyun Bae, Hyuk-Sang Kwon, Michael A Nauck

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 499 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
499citing papers in PubMed, 14 pooled it
21.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

499 citing papers in PubMed, 14 syntheses or guidelines pooled it, 1,037 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pediatric endocrinopathies related to COVID-19: an update.World journal of pediatrics : WJP · 2023
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

439 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Soo Lim *Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. limsoo@snu.ac.kr.ORCID http://orcid.org/0000-0002-4137-1671
Jae Hyun Bae *Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0002-1384-6123
Hyuk-Sang KwonDepartment of Internal Medicine, Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.ORCID http://orcid.org/0000-0003-4026-4572
Michael A NauckDiabetes Division, Katholisches Klinikum Bochum, St Josef-Hospital (Ruhr-Universität Bochum), Bochum, Germany. michael.nauck@rub.de.ORCID http://orcid.org/0000-0002-5749-6954
Korea University Medical Center · KRSeoul National University Bundang Hospital · KRSt. Josef-Hospital · DEThe Catholic University of Korea Yeouido St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Initial studies found increased severity of coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in patients with diabetes mellitus. Furthermore, COVID-19 might also predispose infected individuals to hyperglycaemia. Interacting with other risk factors, hyperglycaemia might modulate immune and inflammatory responses, thus predisposing patients to severe COVID-19 and possible lethal outcomes. Angiotensin-converting enzyme 2 (ACE2), which is part of the renin-angiotensin-aldosterone system (RAAS), is the main entry receptor for SARS-CoV-2; although dipeptidyl peptidase 4 (DPP4) might also act as a binding target. Preliminary data, however, do not suggest a notable effect of glucose-lowering DPP4 inhibitors on SARS-CoV-2 susceptibility. Owing to their pharmacological characteristics, sodium-glucose cotransporter 2 (SGLT2) inhibitors might cause adverse effects in patients with COVID-19 and so cannot be recommended. Currently, insulin should be the main approach to the control of acute glycaemia. Most available evidence does not distinguish between the major types of diabetes mellitus and is related to type 2 diabetes mellitus owing to its high prevalence. However, some limited evidence is now available on type 1 diabetes mellitus and COVID-19. Most of these conclusions are preliminary, and further investigation of the optimal management in patients with diabetes mellitus is warranted.

Indexed as

COVID-19 Drug TreatmentAngiotensin-Converting Enzyme 2Blood GlucoseCOVID-19Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease ManagementHumansHypoglycemic AgentsRisk FactorsACE2 protein, humanAngiotensin-Converting Enzyme 2Blood GlucoseHypoglycemic Agents

Identifiers

PMID33188364
PMCPMC7664589
OpenAlexW3103861847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.